Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 1Q09 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 1Q09

Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 1Q09

1Q Revenues: $5.4 billion (-8%)

1Q Earnings: $1.4 billion (-57%)

Comments: Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%). Sales of Cozaar and Hyzaar2 were $839 million (-1%). Januvia sales were $411 million (+51%). Sales of Fosamax and Fosamax Plus D dropped 44% to $261 million due to loss of U.S. marketing exclusivity. Restructuring costs, primarily related to employee separations, were $64 million in the quarter compared to $70 million in 1Q08. R&D expenses were $1.2 billion (+14%), which includes $88 million for the company’s 2008 global restructuring program. Earnings in 1Q08 included a $1.4 billion after-tax gain on a distribution from AstraZeneca LP.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters